Lv5
1002 积分 2023-12-20 加入
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors
9天前
已完结
The evolving landscape of drug targets
10天前
已完结
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer
15天前
已完结
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
16天前
已完结
Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy
16天前
已完结
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
17天前
已完结
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
1个月前
已完结
Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies
1个月前
已完结
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
1个月前
已完结
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
1个月前
已关闭
皖公网安备34019202002308
